cytena
cytena is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at cytena.
cytena is a company.
Key people at cytena.
Key people at cytena.
Cytena is a biotechnology company specializing in high-precision instruments for isolating, dispensing, imaging, analyzing, and handling biological cells, particularly through its patented single-cell dispensing technology.[3][5] It serves academic labs, pharmaceutical companies, and research institutes by automating workflows in areas like stable cell line development, single-cell omics, high-throughput screening, and drug discovery, addressing labor-intensive processes in cell culture and bioprocessing to accelerate therapy development.[1][3][4] As part of the BICO Group (formerly CELLINK), a lab automation leader, Cytena has over 70 employees, 1000+ customers across 6 continents, and products like C.STATION for cell line development and C.WASH PLUS for microplate washing, driving growth in the life sciences sector.[1][5][7][8]
Cytena was founded in 2014 as a spin-off from the University of Freiburg, Germany, building on patented single-cell dispensing technology developed from microsystems engineering expertise to enable gentle, 100% reliable single live cell isolation.[3][4] The founders identified needs for automated, efficient cell line development instruments, akin to inkjet printing with laser fluorescence imaging for real-time cell verification using CMOS cameras and software.[4] Early traction came from first-generation dispensers for sorting by size/shape, evolving to fluorescent markers for viability and protein assessment; acquisition by BICO in 2019 fueled 500% workspace expansion, 600% personnel growth, and adoption in 200+ global labs.[4] A subsidiary, Cytena Bioprocess Solutions (Cytena BPS), launched in 2018 in Asia to focus on microbioreactors like S.NEST for cell line development (CLD), leveraging BICO resources.[2]
Cytena rides the bio-convergence wave, automating life sciences labs amid rising demand for faster biotherapeutics like monoclonal antibodies amid global health challenges (pandemics, chronic diseases).[1][5] Timing aligns with CLD bottlenecks—labor-intensive, costly processes—where microfluidics and AI-driven monitoring cut development timelines, enabling scalable protein manufacturing.[2][4][7] Market forces like BICO's unicorn growth and pharma's shift to automated workflows favor Cytena, influencing the ecosystem by standardizing single-cell precision in omics/screening, lowering research barriers globally, and partnering (e.g., ExcellGene for CHOExpress integration).[1][7] This positions it as a key enabler in the "lab of the future," accelerating therapies via 1000+ customers.[1][3]
Cytena will expand C.STATION/C.WASH deployments and Asian R&D for high-throughput screening with robotics, big data prediction, and real-time analytics, targeting biopharma's CLD needs.[2][7][8] Trends like AI automation and personalized medicine will amplify its role, potentially via more BICO synergies for global scale. Its influence may evolve from niche dispenser leader to comprehensive bioprocess platform, sustaining momentum in healthcare innovation as seen in its post-acquisition surge. This builds on Cytena's core strength: revolutionizing cell handling to make advanced research accessible and efficient.[1][4]
